



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Therapeutic Radiopharmaceuticals in Oncology

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)
- [Endnotes](#)

Policy Number: 028

BCBSA Reference Number: 6.01.60

NCD/LCD: NA

Related Policies

Therapeutic Radiopharmaceuticals in Oncology for the Treatment of Gastroenteropancreatic, Bronchopulmonary, and Thymus Neuroendocrine Tumors (Lutetium 177 dotatate) Prior Authorization Request Form, #[958](#)

Policy

**Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity
Medicare HMO BlueSM and Medicare PPO BlueSM Members**

Prior Authorization Request Form: Therapeutic Radiopharmaceuticals in Oncology

This form **must** be completed and faxed to: **Medical and Surgical: 1-888-282-0780; Medicare Advantage: 1-800-447-2994.**

- Click here for Therapeutic Radiopharmaceuticals in Oncology for the Treatment of Gastroenteropancreatic, Bronchopulmonary, and Thymus Neuroendocrine Tumors (Lutetium 177) dotatate) Prior Authorization Request Form, #[958](#)

LUTETIUM 177 (LU 177) DOTATATE

INITIAL TREATMENT

Lutetium 177 (Lu 177) dotatate treatment is considered **MEDICALLY NECESSARY** when conditions 1 through 8 are met:

1. Patient is an adult (≥ 18 years of age).
2. Patient has documented low or intermediate grade (Ki-67 index $\leq 20\%$), locally advanced or metastatic, gastroenteropancreatic (including foregut, midgut, and hindgut) or bronchopulmonary or thymus neuroendocrine tumor.
3. Patient has documented somatostatin receptor expression of a neuroendocrine tumor as detected by somatostatin receptor–based imaging (^{68}Ga -dotate positron emission tomography or computed tomography, which is preferred) or somatostatin receptor scintigraphy.
4. Patient has documented disease progression while on octreotide long-acting release therapy.

5. Patient is not receiving long-acting somatostatin analogues for at least 4 weeks prior to initiating Lu 177 dotatate.
6. Patients does not have severe renal impairment (creatinine clearance, <30 mL/min).
7. Patient has adequate bone marrow and hepatic function as determined by the treating physician.
8. Patient has documented Karnofsky Performance Status score of 60 or greater.

CONTINUATION OF TREATMENT

Continuation of Lu 177 dotatate is considered **MEDICALLY NECESSARY** when conditions 1 through 5 are met:

1. No recurrent grade 2, 3, or 4 thrombocytopenia (see Table PG1).
2. No recurrent grade 3 or 4 anemia and neutropenia (see Table PG1).
3. No recurrent hepatotoxicity*
4. No recurrent grade 3 or 4 nonhematologic toxicity (see Table PG1).
5. Renal toxicity requiring a treatment delay of 16 weeks or longer.**

Lu 177 dotatate treatment is considered **INVESTIGATIONAL** in all other situations in which the above criteria are not met.

Lu 177 dotatate treatment greater than a total of 4 doses as per the Food and Drug Administration–approved regimen is considered **INVESTIGATIONAL**.

*Lu 177 dotatate should be discontinued permanently if the patient develops hepatotoxicity defined as bilirubinemia greater than 3 times the upper limit of normal (grade 3 or 4), or hypoalbuminemia less than 30 g/L with a decreased prothrombin ratio less than 70%.

**Lu 177 dotatate should be discontinued permanently if patient develops renal toxicity defined as a creatinine clearance of less than 40 mL/min calculated using Cockcroft-Gault equation with actual body weight, or 40% increase in baseline serum creatinine, or 40% decrease in baseline creatinine clearance calculated using Cockcroft-Gault equation with actual body weight.

Table 1 describes the grading of severity used in the Common Toxicity Criteria for Adverse Events (version 4.03).

Table 1. Common Toxicity Criteria for Adverse Events, Version 4.03

Grade	Description
1	Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
2	Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living and refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.
3	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living and refer to refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
4	Life-threatening consequences; urgent intervention indicated.
5	Death related to adverse event.

IOBENGUANE I-131

Iobenguane I-131 is considered **INVESTIGATIONAL** for the treatment of patients aged 12 and older with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.¹

Iobenguane I-131 treatment is considered **INVESTIGATIONAL** in all other situations not listed above.¹

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is required for Lutetium 177 dotatate.* Iobenguane I-131 treatment is not a covered service.
Commercial PPO and Indemnity	Prior authorization is required for Lutetium 177 dotatate.* Iobenguane I-131 treatment is not a covered service.
Medicare HMO BlueSM	Prior authorization is required for Lutetium 177 dotatate.* Iobenguane I-131 treatment is not a covered service.
Medicare PPO BlueSM	Prior authorization is required for Lutetium 177 dotatate.* Iobenguane I-131 treatment is not a covered service.

*Prior Authorization Request Form: Therapeutic Radiopharmaceuticals in Oncology

This form **must** be completed and faxed to: **Medical and Surgical: 1-888-282-0780; Medicare Advantage: 1-800-447-2994.**

- Click here for Therapeutic Radiopharmaceuticals in Oncology for the Treatment of Gastroenteropancreatic, Bronchopulmonary, and Thymus Neuroendocrine Tumors (Lutetium 177 dotatate) Prior Authorization Request Form, #958

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above **medical necessity criteria MUST** be met for the following codes to be covered for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

HCPCS Codes

HCPCS codes:	Code Description
A9513	Lutetium lu 177, dotatate, therapeutic, 1 millicurie

The following HCPCS codes are considered investigational for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

HCPCS Codes

HCPCS codes:	Code Description
C9407	Iodine i-131 iobenguane, diagnostic, 1 millicurie
C9408	Iodine i-131 iobenguane, therapeutic, 1 millicurie

Description

NEUROENDOCRINE TUMORS

Neuroendocrine tumors are a heterogeneous group of tumors that originate from the neuroendocrine cells in the diffuse neuroendocrine system anywhere in the body but more commonly in the gastrointestinal tract and the respiratory system. Approximately 61% of all neuroendocrine tumors originate from gastrointestinal system or pancreas and are referred to as gastroenteropancreatic neuroendocrine tumors. Lung neuroendocrine tumors may also be referred to as pulmonary neuroendocrine tumors, pulmonary carcinoids, or bronchopulmonary neuroendocrine tumors. Gastroenteropancreatic neuroendocrine tumors may further be characterized as functional or nonfunctional based on whether they secrete hormones that result in clinical symptoms particularly serotonin, which results in “carcinoid syndrome” that is characterized by flushing and diarrhea.

Neuroendocrine tumors are classified as orphan diseases by the Food and Drug Administration (FDA). Based on an analysis of Surveillance, Epidemiology, and End Results Program registry data from 1973 to 2012, the overall incidence of neuroendocrine tumors has been reported to be in the range of 6.98 per 100,000 people per year.¹

Diagnosis

Neuroendocrine tumors are not easy to diagnose because of the rarity of the condition. Symptoms are often nonspecific or mimic other disorders such as irritable bowel syndrome (in the case of gastroenteropancreatic neuroendocrine tumors) or asthma (in the case of a lung neuroendocrine tumors) resulting in an average diagnosis delay of 5 to 7 years after symptom onset.² In many cases, diagnosis is incidental to imaging for other unrelated cause. Most gastroenteropancreatic neuroendocrine tumors express somatostatin receptors that can be imaged using a radiolabeled form of the somatostatin analogue octreotide (eg, ¹¹¹In pentetreotide).

Treatment Approach

There is a general lack of prospective data to guide the treatment of neuroendocrine tumors. Gastroenteropancreatic neuroendocrine tumors are chemotherapy-responsive neoplasms, and platinum-based chemotherapy represents the backbone of treatment for both early and advanced-stage tumors.³ Surgery alone or followed by chemotherapy along with treatment of hormone-related symptoms may be the initial approach for localized disease. For asymptomatic patients with slow progression, observation with routine surveillance imaging is an option. The prognosis for patients with metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors is highly variable. Based on retrospective analyses of large databases, the prognosis for patients with metastatic gastroenteropancreatic neuroendocrine tumors is variable. The median overall survival (from diagnosis) for patients with metastatic pancreatic neuroendocrine tumors has been reported to range from 2 to 5.8 years^{4,5} while the median overall survival for small bowel neuroendocrine tumors has been reported as 7.9 years.⁶

Pharmacologic Treatment

First-Line Treatment Options

Somatostatin Analogues (Octreotide and Lanreotide)

Somatostatin is a peptide that binds to somatostatin receptors that are expressed in a majority of carcinoid tumors and inhibits the secretion of a broad range of hormones. Somatostatin analogues (eg, octreotide, lanreotide) were initially developed to manage the hormonal symptoms related to neuroendocrine tumors, they were found to exert antiproliferative activity, and clinical studies have demonstrated prolonged progression-free survival (PFS) in patients with neuroendocrine tumors treated with somatostatin analogues.^{7,8} However, the role of somatostatin analogues in patients with nonfunctioning neuroendocrine tumors is unclear.⁹

Commercially available long-acting release forms of octreotide and lanreotide (eg, Sandostatin LAR, Somatuline Depot), which are administered intramuscularly on a monthly basis, have largely eliminated the need for daily self-injection of short-acting subcutaneous formulations.^{10,11}

Second-Line Treatment Options

Currently, there are no data to support a specific sequence of therapies and only streptozocin, everolimus, and sunitinib are FDA approved for the treatment of pancreatic neuroendocrine tumors.

Mechanistic Target of Rapamycin Inhibitors

The mechanistic target of rapamycin is an enzyme that regulates cell metabolism and proliferation in response to environmental stimuli. It is upregulated in a variety of malignancies in response to stimulation by growth factors and cytokines. Whole-exome genomic analysis has shown that approximately 15% of pancreatic neuroendocrine tumors are associated with somatic variants in genes associated with the mechanistic target of rapamycin pathway.¹² Everolimus, an oral mechanistic target of rapamycin inhibitor, has been shown to significantly prolonged PFS vs placebo in patients with pancreatic neuroendocrine tumors (RADIANT-3 trial),¹³ and lung and gastrointestinal neuroendocrine tumors nonfunctional (RADIANT-4 trial).¹⁴ Note that everolimus is approved by FDA for adults with progressive neuroendocrine tumors of pancreatic origin and adults with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced or metastatic. The RADIANT-2 trial patients with progressive advanced neuroendocrine tumors associated with carcinoid syndrome failed to show a statistically significant improvement in the primary end point of PFS.¹⁵

Tyrosine Kinase Receptor Inhibitors

Neuroendocrine tumors frequently overexpress the vascular endothelial growth factor and receptor. Sunitinib, is a multi-targeted tyrosine kinase inhibitor that targets multiple signaling pathways and growth factors and receptors including vascular endothelial growth factor and receptor 1, 2, and 3.¹² It has been shown that daily sunitinib at a dose of 37.5 mg improves PFS, overall survival, and the overall response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.¹⁶ Note that sunitinib is FDA approved for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.

Chemotherapy

Response to chemotherapy for advanced neuroendocrine tumors of the gastrointestinal tract and lung is highly variable and, at best, modest. Tumor response rates are generally low and no PFS benefit has been clearly demonstrated. Therefore, the careful selection of patients is critical to maximize the chance of response and avoid unnecessary toxicity. In advanced neuroendocrine tumors, platinum-based regimens are generally used. They include cisplatin and etoposide (most widely used), carboplatin and etoposide, 5-fluorouracil, capecitabine, dacarbazine, oxaliplatin, streptozocin, and temozolomide.¹⁷

Lutetium 177 Dotatate

Lutetium 177 dotatate is a radiolabeled-somatostatin analogue that binds to somatostatin receptor expressing cells, including malignant somatostatin receptor–positive tumors. It is then internalized and beta particle emission from lutetium 177 induces cellular damage by formation of free radicals in somatostatin receptor–positive and neighboring cells.

Iobenguane I-131

Iobenguane I-131 is a radioiodinated synthetic analogue of the neurotransmitter norepinephrine. Iobenguane localizes to adrenergic tissue and, in radioiodinated forms, may be used to image or eradicate tumor cells that take up and metabolize norepinephrine.

Summary

Radiopharmaceuticals are composed of a radioisotope bond to an organic molecule and are used for diagnostic and therapeutic purposes. The organic molecule conveys the radioisotope to specific organs, tissues, or cells. Lutetium 177 (Lu 177) dotatate, classified as peptide receptor radionuclide therapy is a radiolabeled-somatostatin analogue that binds to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors such as neuroendocrine tumors. It is then internalized and beta particle emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive and neighboring cells.

For individuals with a treatment-refractory gastroenteropancreatic neuroendocrine tumor including

foregut, midgut, and hindgut tumors who receive Lu 177 dotatate, the evidence includes a randomized, open-labeled trial and a retrospective cohort study. Relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. The randomized controlled trial results showed a consistent statistically significant and clinically meaningful effect on overall response rate, progression-free survival, and overall survival among patients treated with Lu 177 dotatate compared to those treated with long-acting octreotide. The results of the retrospective cohort study were consistent with the treatment effect observed in the randomized controlled trial and provide additional support for a clinical benefit of Lu 177 dotatate in patients with a gastroenteropancreatic neuroendocrine tumor. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with a treatment-refractory bronchopulmonary or thymus neuroendocrine tumors who receive Lu 177 dotatate, the evidence includes a retrospective cohort study. Relevant outcomes are overall survival, disease-specific survival, quality of life, and treatment-related mortality and morbidity. The retrospective cohort study included a small number of patients with bronchopulmonary (n=23) or thymus (n=2) neuroendocrine tumors. Among the 23 patients with bronchopulmonary neuroendocrine tumor, the median progression-free survival was 20 months, the median time to progression was 25 months, and median overall survival was 52 months. Stratified results of 2 patients with thymus neuroendocrine tumors were not reported. The Food and Drug Administration in its review of the ERASMUS study for patients with gastroenteropancreatic neuroendocrine tumor concluded that time to event analyses such as time to progression, progression-free survival, and overall survival were not interpretable in the context of the single-arm ERASMUS study because of missing data at baseline, high dropout rates and open-label design of the study. Of note, despite the current evidence base, National Comprehensive Cancer Network guidelines give a category 2A recommendation for use of Lu 177 dotatate for the treatment of bronchopulmonary and thymic locoregional advanced or distant metastases neuroendocrine tumors if there is clinically significant tumor burden and low grade (typical) or evidence of progression or intermediate grade (atypical). The evidence is insufficient to determine the effects of technology on health outcomes.

Iobenguane I-131 The evidence is insufficient to determine the effects of technology on health outcomes for the treatment of patients aged 12 and older with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.

Policy History

Date	Action
2/2019	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
1/2019	Clarified coding information.
12/2018	New medical policy describing medically necessary and investigational indications. The use of Lutathera® (lutetium 177 dotatate) is considered medically necessary for patients with gastroenteropancreatic, bronchopulmonary, and thymus neuroendocrine tumors. Effective 12/1/2018. The use of Azedra® (iobenguane I-131) is considered investigational for patients aged 12 and older with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. Effective 12/1/2018.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

References

1. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. *JAMA Oncol.* Oct 1 2017;3(10):1335-1342. PMID 28448665
2. Frilling A, Akerstrom G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. *Endocr Relat Cancer.* Oct 2012;19(5):R163-185. PMID 22645227
3. Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. *Cancer.* Sep 15 2014;120(18):2814-2823. PMID 24771552
4. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol.* Jun 20 2008;26(18):3063-3072. PMID 18565894
5. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. *Pancreas.* Apr 2009;38(3):255-258. PMID 19066493
6. Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. *Endocr Relat Cancer.* Apr 2013;20(2):187-196. PMID 23319495
7. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol.* Oct 1 2009;27(28):4656-4663. PMID 19704057
8. Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Ann Oncol.* Aug 2015;26(8):1604-1620. PMID 25646366
9. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). *Gut.* Jan 2012;61(1):6-32. PMID 22052063
10. Öberg K, Leyden J, Goldstein G, et al. Neuroendocrine tumor European patient experience: results from the first global NET patient survey - a collaboration between the International Neuroendocrine Cancer Alliance and Novartis [abstract]. *Endocrine Abstracts.* 2015;37:EP1139. PMID
11. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. *Cancer.* Feb 15 2000;88(4):770-776. PMID 10679645
12. Strosberg J. Advances in the treatment of pancreatic neuroendocrine tumors (pNETs). *Gastrointest Cancer Res.* Jul 2013;6(4 Suppl 1):S10-12. PMID 24312683
13. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med.* Feb 10 2011;364(6):514-523. PMID 21306238
14. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *Lancet.* Mar 5 2016;387(10022):968-977. PMID 26703889
15. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet.* Dec 10 2011;378(9808):2005-2012. PMID 22119496
16. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med.* Feb 10 2011;364(6):501-513. PMID 21306237
17. Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. *Neuroendocrinology.* 2016;103(2):186-194. PMID 26731334
18. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. *N Engl J Med.* Jan 12 2017;376(2):125-135. PMID 28076709
19. Food and Drug Administration, Center for Drug Evaluation and Research. Application Number: 208700Orig1s000 Multi-Disciplinary Review. Addendum to Review, NDA 208700. 2018; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208700Orig1s000MultidisciplineR.pdf. Accessed July 3, 2018.

20. Novartis Inc. Lutathera® (lutetium Lu 177 dotatate) injection, for intravenous use administration of Lutathera (Prescribing Label). 2018; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf. Accessed July 3, 2018.
21. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol*. May 1 2008;26(13):2124-2130. PMID 18445841
22. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. *Clin Cancer Res*. Aug 15 2017;23(16):4617-4624. PMID 28428192
23. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed July 3, 2018.

Endnotes

¹ Based on expert opinion